ClinicalTrials.gg

Program

Sodium Nitrite

Also written as “Sodium nitrite”, “AIR-001 SAD dose level 1” and “AIR-001 SAD dose level 2”.

Its studies are mostly in Pulmonary Arterial Hypertension · Subarachnoid Hemorrhage · alpha 1-Antitrypsin Deficiency · COVID-19 · Diabetes Mellitus, led by 4 companies.

Furthest: phase 2, since Nov 8, 201210 company-led studies, 1 open or runningNext primary completion: Nov 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Aires Pharmaceuticals40 open or runningphase 2since Nov 8, 2012Dec 22, 2008none ahead
Hope Pharmaceuticals30 open or runningphase 2since Mar 31, 2009Mar 31, 2009none ahead
TheraVasc20 open or runningphase 2since Jun 28, 2011Jun 28, 2011none ahead
AIRNA11 open or runningphase 1since Feb 19, 2026Feb 19, 2026Nov 2028phase 1 · NCT07431112

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 22, 2008First study: phase 1 study in Pulmonary Arterial HypertensionNew to Aires PharmaceuticalsAires Pharmaceuticals · NCT00814645 · 25 enrolled · United States
  2. Mar 31, 2009Hope Pharmaceuticals's first study: phase 2 study in Subarachnoid HemorrhageNew to Hope PharmaceuticalsHope Pharmaceuticals · NCT00873015 · 19 enrolled · United States
  3. Jun 28, 2011TheraVasc's first study: phase 2 study in Peripheral Arterial DiseaseNew to TheraVascTheraVasc · NCT01401517 · 55 enrolled · United States
  4. Aug 1, 2011Phase 1 study in Hypertension, PulmonaryAires Pharmaceuticals · NCT01409122 · 42 enrolled · United States
  5. Nov 8, 20122 phase 2 studies in Pulmonary Arterial HypertensionAires Pharmaceuticals · NCT01725269, NCT01725256
  6. Feb 19, 2014Phase 2 study in Subarachnoid HemorrhageHope Pharmaceuticals · NCT02176837 · 6 enrolled · United States
  7. Apr 1, 2015Phase 2 study in Diabetes MellitusTheraVasc · NCT02412852 · 26 enrolled · United States
  8. May 21, 2020Phase 2 study in COVID-19Hope Pharmaceuticals · NCT04401527 · United States
  9. Feb 19, 2026AIRNA's first study: phase 1 study in alpha 1-Antitrypsin DeficiencyNew to AIRNAAIRNA · NCT07431112 · 54 planned · Australia, Georgia, Germany and more

Ahead

  1. Nov 2028Primary completion: phase 1 study in alpha 1-Antitrypsin DeficiencyAIRNA · NCT07431112

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07431112alpha 1-Antitrypsin Deficiency · Australia, Georgia, Germany and more1RecruitingAIRNANov 202854
NCT04401527COVID-19 · United States2WithdrawnHope PharmaceuticalsAug 15, 20200
NCT02412852Diabetes Mellitus · United States2CompletedTheraVascDec 7, 201526
NCT02176837Subarachnoid Hemorrhage · United States2TerminatedHope PharmaceuticalsJan 15, 20176
NCT01725269Pulmonary Arterial Hypertension · United States, Australia, Hungary2TerminatedAires PharmaceuticalsApr 201417
NCT01725256Pulmonary Arterial Hypertension · United States, Australia, Hungary2TerminatedAires PharmaceuticalsFeb 201429
NCT01409122Hypertension, Pulmonary · United States1CompletedAires PharmaceuticalsJan 201242
NCT01401517Peripheral Arterial Disease · United States2CompletedTheraVascJan 201355
NCT00873015Subarachnoid Hemorrhage · United States2CompletedHope PharmaceuticalsNov 201019
NCT00814645Pulmonary Arterial Hypertension · United States1CompletedAires PharmaceuticalsApr 200925

How it is read

Names in the registry

  • “Sodium Nitrite”, 2 entries
  • “Sodium nitrite”, 2 entries
  • “AIR-001 SAD dose level 1”, 1 entry
  • “AIR-001 SAD dose level 2”, 1 entry
  • “AIR-001 SAD dose level 3”, 1 entry

Codes read as this program: AIR001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.